Zogenix To Pay $250m Upfront To Buy Modis For Ultra-Orphan Drug
The takeover will diversify Zogenix’s pipeline through the addition of MT1621, a drug that improved the probability of survival in patients with an inherited mitochondrial DNA depletion disorder.
You may also be interested in...
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Like his previous move, Papa joins a pharma firm making a significant organizational shift to cut costs and increase revenues after extended period of higher spending and slowing income.
After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.